Clinical trial
Examine National Characteristics & Outcome Measures of GERD Patients Using the…
NCT00392002 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00392002 |
|---|---|
| Title | Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response |
| Official title | A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS]. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux |
| Intervention type | Drug |
| Interventions | Esomeprazole |
| Enrollment | 2,000 |
| Start date | Oct 1, 2005 |
| Completion | May 1, 2007 |
| First posted | Oct 25, 2006 |
| Last update posted | Jan 25, 2008 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: